Artivion Inc (AORT)

Currency in USD
36.60
-4.05(-9.96%)
Closed·
36.55-0.05(-0.14%)
·
Unusual trading volume
AORT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
33.8539.07
52 wk Range
21.9748.25
Key Statistics
Prev. Close
40.65
Open
38.95
Day's Range
33.85-39.07
52 wk Range
21.97-48.25
Volume
1.43M
Average Volume (3m)
361.89K
1-Year Change
21.7565%
Book Value / Share
9.46
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AORT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
51.43
Upside
+40.52%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Artivion Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Artivion Company Profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Artivion Inc Earnings Call Summary for Q4/2025

  • Artivion exceeded Q4 2025 EPS expectations by 183.33% ($0.17 vs $0.06 forecast), driving a 1.36% stock increase to $40.55 despite slightly missing revenue targets.
  • Q4 revenue grew 18.5% year-over-year to $118.3M, with stent grafts and On-X heart valves showing exceptional growth of 36% and 24% respectively.
  • Adjusted EBITDA reached $22.7M (up 29% YoY) with a 19.2% margin for Q4 and 20.2% for the full year, generating positive free cash flow of approximately $1M for 2025.
  • Management projects 10-14% revenue growth for 2026 ($486-504M), with continued strength in On-X and stent graft segments expected at mid-teens and low twenties growth rates.
  • CEO Pat Mackin described 2025 as 'a standout year,' noting they're 'in the first inning' regarding market opportunity for their Ascending Aortic Dissection Solution (AMDS).
Last Updated: 12/02/2026, 22:44
Read Full Transcript

Compare AORT to Peers and Sector

Metrics to compare
AORT
Peers
Sector
Relationship
P/E Ratio
179.3x−2.4x−0.5x
PEG Ratio
1.080.640.00
Price/Book
3.9x1.9x2.6x
Price / LTM Sales
4.0x1.9x3.3x
Upside (Analyst Target)
44.8%125.6%47.1%
Fair Value Upside
Unlock23.7%5.8%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 51.43
(+40.52% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Ladenburg Thalmann
Hold41.00+12.02%40.00Maintain13/02/2026
Canaccord Genuity
Buy48.00+31.15%51.00Maintain13/02/2026
Oppenheimer
Buy50.00+36.61%-Maintain05/02/2026
Canaccord Genuity
Buy51.00+39.34%-Maintain17/12/2025
Canaccord Genuity
Buy51.00+39.34%-Maintain17/12/2025

Earnings

Latest Release
Feb 12, 2026
EPS / Forecast
0.17 / 0.06
Revenue / Forecast
116.00M / 116.42M
EPS Revisions
Last 90 days

People Also Watch

268.41
ESE
-1.59%
322.71
PIPR
+0.43%
163.74
JBTM
+0.23%

FAQ

What Is the Artivion (AORT) Share Price Today?

The live Artivion share price today is 36.60

What Stock Exchange Does Artivion (AORT) Trade On?

Artivion is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Artivion?

The stock symbol (also called a 'ticker') for Artivion is "AORT."

What Is the Current Artivion Market Cap?

As of today, Artivion market capitalisation is 1.75B.

What Is Artivion's (AORT) Earnings Per Share (TTM)?

The Artivion EPS is currently 0.22 (Trailing Twelve Months).

When Is the Next Artivion Earnings Date?

Artivion's next earnings report will be released on 30/04/2026.

Is AORT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Artivion moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Artivion Stock Split?

Artivion has split 2 times. (See the AORT stock split history page for full effective split date and price information.)

How Many Employees Does Artivion Have?

Artivion has 1600 employees.

What is the current trading status of Artivion (AORT)?

As of 15 Feb 2026, Artivion (AORT) is trading at a price of 36.60, with a previous close of 40.65. The stock has fluctuated within a day range of 33.85 to 39.07, while its 52-week range spans from 21.97 to 48.25.

What Is Artivion (AORT) Price Target According to Analysts?

The average 12-month price target for Artivion is USD51.43, with a high estimate of USD58 and a low estimate of USD41. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +40.52% Upside potential.

What Is the AORT Premarket Price?

AORT's last pre-market stock price is 37.56. The pre-market share volume is 580.00, and the stock has decreased by -3.09, or -7.60%.

What Is the AORT After Hours Price?

AORT's last after hours stock price is 36.55, the stock has decreased by -0.05, or -0.14%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.